Investor Relations

We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (formerly BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN).

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University

Corporate

Founded in 2004; based in Cambridge and Jerusalem

CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure

Financial

Market capitalization: $33.2 million (end Q2 2019)

Share capitalization: 7.4 million ADSs outstanding (NASDAQ: ANCN) equivalent to 37.1 million outstanding shares

11.1 million ADSs fully diluted, equivalent to 55.4 million shares

Cash: $27 million (end Q2 2019), no debt

Stock Quote

Nasdaq

Intraday delay: 15 minutes

Stock Chart 

Intraday delay: 15 minutes

Press Releases

Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (September 20, 2019)
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference (September 3, 2019)
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results (August 5, 2019)
Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange (June 18, 2019)
Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development (May 29, 2019)
Anchiano Therapeutics Reports First Quarter 2019 Financial Results (May 22, 2019)
Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference (March 14, 2019)
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Sock Exchange (March 14, 2019)
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results  (March 12, 2019)
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering  (February 14, 2019)
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering  (February 12, 2019)
Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering (January 7, 2019)
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (November 26, 2018)
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer (November 26, 2018)
Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to its Board of Directors (November 12, 2018)

READ MORE

SEC Company Filings


Filing DateFormDescriptionDownload
8/13/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
8/6/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
7/22/198-KSecurities to be offered to employees in employee benefit plansPDF
7/8/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
6/18/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/28/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/22/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
4/24/1920-F/A[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/25/1920-KAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
3/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/13/19424B4Prospectus [Rule 424(b)(4)]PDF
2/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/11/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/8/198-A12BRegistration of securities [Section 12(b)]PDF
2/8/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/7/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/30/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/7/19F-1Registration statement for certain foreign private issuers PDF
Anchiano Therapeutics Ltd. CIK#: 0001534248 (see all company filings)

Contact Investor Relations

Ashley Robinson, LifeSci Advisors
Email: arr@lifesciadvisors.com

Presentations

Baird’s 2019 Global Healthcare Conference | September 5, 2019

Click here for webcast 

 

MIXiii-BIOMED 2019 | May 16, 2019 

 

 

Oppenheimer 29th Annual Healthcare Conference | March 20, 2019 

 

Corporate Presentation | January 2019